UNLABELLED: Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength. INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength. METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated. RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001). CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
RCT Entities:
UNLABELLED: Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength. INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength. METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated. RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001). CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
Authors: Michael R McClung; Javier San Martin; Paul D Miller; Roberto Civitelli; Francisco Bandeira; Molly Omizo; David W Donley; Gail P Dalsky; Erik F Eriksen Journal: Arch Intern Med Date: 2005 Aug 8-22
Authors: Dennis M Black; John P Bilezikian; Kristine E Ensrud; Susan L Greenspan; Lisa Palermo; Trisha Hue; Thomas F Lang; Joan A McGowan; Clifford J Rosen Journal: N Engl J Med Date: 2005-08-11 Impact factor: 91.245
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen Journal: N Engl J Med Date: 2003-09-20 Impact factor: 91.245
Authors: Harry K Genant; Thomas Lang; Thomas Fuerst; Karen V Pinette; Chunmei Zhou; Daniel Thiebaud; Adolfo Diez-Perez Journal: Bone Date: 2004-11 Impact factor: 4.398
Authors: Joy N Tsai; Hang Lee; Natalie L David; Richard Eastell; Benjamin Z Leder Journal: Lancet Diabetes Endocrinol Date: 2019-08-22 Impact factor: 32.069
Authors: Julio Carballido-Gamio; Aihong Yu; Ling Wang; Yongbin Su; Andrew J Burghardt; Thomas F Lang; Xiaoguang Cheng Journal: Ann Biomed Eng Date: 2019-05-31 Impact factor: 3.934
Authors: Cheng Li; Dakai Jin; Cheng Chen; Elena M Letuchy; Kathleen F Janz; Trudy L Burns; James C Torner; Steven M Levy; Punam K Saha Journal: Med Phys Date: 2015-08 Impact factor: 4.071
Authors: Lang Yang; Annabel C Burton; Mike Bradburn; Carrie M Nielson; Eric S Orwoll; Richard Eastell Journal: J Bone Miner Res Date: 2012-11 Impact factor: 6.741